LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program
Rhea-AI Summary
LifeMD (Nasdaq: LFMD) launched Novo Nordisk's industry-first Wegovy® (semaglutide) telehealth subscription program on March 31, 2026, expanding its commercial collaboration with Novo Nordisk. Eligible patients can receive structured pricing with up to $1,200 annual savings for injectable Wegovy and $600 for oral therapy.
The program offers end-to-end virtual care across all 50 states, ongoing clinical oversight, nationwide diagnostic testing, and simplified billing, and is available at LifeMD's weight management site.
Positive
- Up to $1,200 annual savings for injectable Wegovy subscriptions
- $600 annual savings for oral Wegovy subscriptions
- Expanded commercial collaboration with Novo Nordisk across Wegovy and Ozempic since 2025
- Nationwide telehealth coverage with virtual visits and clinical oversight in all 50 states
Negative
- None.
News Market Reaction – LFMDP
In the Mar 31 session, LFMDP gained 1.25%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 24 | Dividend declaration | Positive | +0.9% | Announced cash dividend on 8.875% Series A preferred shares. |
| Mar 16 | Management change | Positive | +1.6% | Appointed new CFO and expanded leadership team with stock-based inducement. |
| Mar 09 | Earnings report | Positive | +2.5% | Reported strong 2025 revenue and adjusted EBITDA growth with solid cash position. |
| Mar 03 | Conference participation | Neutral | -0.1% | Disclosed participation in two healthcare investor conferences in March. |
| Feb 23 | Earnings date set | Neutral | -1.2% | Announced date and time for Q4 and full-year 2025 results call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent corporate and financial updates have generally seen modestly positive price reactions, with earnings and leadership news aligning with upward moves.
Over the past several weeks, LifeMD has delivered a steady flow of updates. On March 9, 2026, full-year 2025 results showed revenue of $194.1M and adjusted EBITDA of $15.3M, with a positive price reaction. Subsequent news included an earnings date notice and participation in investor conferences. Governance and capital actions featured a quarterly preferred dividend declared on March 24, 2026 and a new CFO appointment with equity inducement. Today’s collaboration-focused announcement fits into this pattern of ongoing franchise and capital development.
Key Terms
telehealth technical
wegovy medical
semaglutide medical
glp-1 medical
diagnostic testing medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Delivering up to
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the launch of Novo Nordisk's new Wegovy® (semaglutide) subscription program — the first and only GLP-1 subscription offering of its kind — now available through LifeMD. The program meaningfully expands patient access to branded GLP-1 therapy and supports treatment adherence with significant cost savings.
The subscription model marks a significant evolution in branded GLP-1 distribution. Eligible patients who enroll in the multi-month Wegovy® program through LifeMD now benefit from structured pricing: up to
"Our inclusion in the Wegovy® subscription program is a natural extension of our established relationship with Novo Nordisk," said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD. "This program deepens the value of our collaboration and adds meaningful financial savings for the patients we serve. By integrating subscription pricing with our comprehensive remote patient care model, we're delivering the future of obesity treatment — branded therapy that is more accessible, affordable, and clinically supported."
Since its launch in 2025, LifeMD's collaboration with Novo Nordisk has expanded from an initial NovoCare® Pharmacy integration into a multi-faceted commercial collaboration spanning injectable and oral Wegovy® and Ozempic®. LifeMD is recognized as a telehealth provider on both the NovoCare® and Wegovy® websites — a distinction that underscores the depth and durability of the relationship.
Patients accessing Wegovy through LifeMD benefit from a comprehensive, end-to-end care experience that includes: virtual visits with LifeMD's affiliated medical group across all 50 states; ongoing clinical oversight and care management; access to nationwide diagnostic testing; and simplified billing and payment.
The Wegovy® subscription program is now available to eligible patients through LifeMD at https://lifemd.com/weight-management/.
About LifeMD, Inc.
LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women’s health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com.
Cautionary Note Regarding Forward Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” “predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.
Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.
Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.
Investor Contact
Atul Kavthekar, Chief Financial Officer
investors@lifemd.com
Media Contact
Jessica Friedeman, Chief Business Officer
press@lifemd.com
